A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 313 participants.

Also called NCT02072226

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 313 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02072226
Other papers using this trial's data
  • Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial JAMA, 2018-07-10 DOI, PubMed 29998337, PMC6583516 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02072226. Randomized; double masking; primary purpose treatment. Start 2014-05-31 (actual); primary completion 2017-03-22 (actual). Results posted on 2018-07-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
Acronym
PRISMS
Condition
Stroke
Intervention (Drug)
Alteplase
Intervention (Drug)
Alteplase Placebo
Intervention (Drug)
Aspirin
Intervention (Drug)
Aspirin Placebo
Lead sponsor
Genentech, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02072226
Content hash
89c0c06764a41d2a4ed08f29450f79ff678349244cf589da9118a73aac40e855